Recursion Pharmaceuticals disclosed a workforce reduction of approximately 20%—about 160 jobs—citing pipeline pruning and challenges in biotech capital markets. The restructuring aims to optimize operations and extend cash runway into late 2027 while reflecting a narrowing focus on oncology and rare disease research. Despite the cuts, Recursion forecasts substantial milestone-driven income and continues leveraging its AI-powered drug discovery platform.